King's College London

Research portal

Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges

Research output: Contribution to journalReview article

Standard

Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine : Historical Importance, Current Innovations, and Future Challenges. / Jackson, Jessica A; Hungnes, Ingebjørg N; Ma, Michelle T; Rivas, Charlotte.

In: Bioconjugate Chemistry, Vol. 31, No. 3, 18.03.2020, p. 483-491.

Research output: Contribution to journalReview article

Harvard

Jackson, JA, Hungnes, IN, Ma, MT & Rivas, C 2020, 'Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges', Bioconjugate Chemistry, vol. 31, no. 3, pp. 483-491. https://doi.org/10.1021/acs.bioconjchem.0c00015

APA

Jackson, J. A., Hungnes, I. N., Ma, M. T., & Rivas, C. (2020). Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges. Bioconjugate Chemistry, 31(3), 483-491. https://doi.org/10.1021/acs.bioconjchem.0c00015

Vancouver

Jackson JA, Hungnes IN, Ma MT, Rivas C. Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges. Bioconjugate Chemistry. 2020 Mar 18;31(3):483-491. https://doi.org/10.1021/acs.bioconjchem.0c00015

Author

Jackson, Jessica A ; Hungnes, Ingebjørg N ; Ma, Michelle T ; Rivas, Charlotte. / Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine : Historical Importance, Current Innovations, and Future Challenges. In: Bioconjugate Chemistry. 2020 ; Vol. 31, No. 3. pp. 483-491.

Bibtex Download

@article{1280ab59eaef4d93890b6b1fa639cc95,
title = "Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges",
abstract = "Molecular radiopharmaceuticals based on bioconjugates of chelators with peptides and proteins have had significant clinical impact in the diagnosis and treatment of several types of cancers. In the 1990s, indium-111 and yttrium-90 labeled chelator-peptide/protein conjugates established the clinical utility of these radiopharmaceuticals for receptor-targeted γ-scintigraphy imaging and systemic radiotherapy. Second-generation bioconjugates based on peptides targeting the somatostatin II receptor and the prostate-specific membrane antigen are now widely used for management of neuroendocrine and prostate cancer, respectively. These bioconjugates are typically radiolabeled with gallium-68 for imaging of target receptor expression with positron emission tomography, and the β--emitter, lutetium-177, for targeted radiotherapy. Innovations in radioisotope technology and biomolecular therapies are likely to drive the future clinical development of radiopharmaceuticals based on radiometals. New chelator-peptide and chelator-protein bioconjugates will underpin nuclear medicine advances in molecular imaging and radiotherapy.",
author = "Jackson, {Jessica A} and Hungnes, {Ingebj{\o}rg N} and Ma, {Michelle T} and Charlotte Rivas",
year = "2020",
month = mar,
day = "18",
doi = "10.1021/acs.bioconjchem.0c00015",
language = "English",
volume = "31",
pages = "483--491",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "3",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine

T2 - Historical Importance, Current Innovations, and Future Challenges

AU - Jackson, Jessica A

AU - Hungnes, Ingebjørg N

AU - Ma, Michelle T

AU - Rivas, Charlotte

PY - 2020/3/18

Y1 - 2020/3/18

N2 - Molecular radiopharmaceuticals based on bioconjugates of chelators with peptides and proteins have had significant clinical impact in the diagnosis and treatment of several types of cancers. In the 1990s, indium-111 and yttrium-90 labeled chelator-peptide/protein conjugates established the clinical utility of these radiopharmaceuticals for receptor-targeted γ-scintigraphy imaging and systemic radiotherapy. Second-generation bioconjugates based on peptides targeting the somatostatin II receptor and the prostate-specific membrane antigen are now widely used for management of neuroendocrine and prostate cancer, respectively. These bioconjugates are typically radiolabeled with gallium-68 for imaging of target receptor expression with positron emission tomography, and the β--emitter, lutetium-177, for targeted radiotherapy. Innovations in radioisotope technology and biomolecular therapies are likely to drive the future clinical development of radiopharmaceuticals based on radiometals. New chelator-peptide and chelator-protein bioconjugates will underpin nuclear medicine advances in molecular imaging and radiotherapy.

AB - Molecular radiopharmaceuticals based on bioconjugates of chelators with peptides and proteins have had significant clinical impact in the diagnosis and treatment of several types of cancers. In the 1990s, indium-111 and yttrium-90 labeled chelator-peptide/protein conjugates established the clinical utility of these radiopharmaceuticals for receptor-targeted γ-scintigraphy imaging and systemic radiotherapy. Second-generation bioconjugates based on peptides targeting the somatostatin II receptor and the prostate-specific membrane antigen are now widely used for management of neuroendocrine and prostate cancer, respectively. These bioconjugates are typically radiolabeled with gallium-68 for imaging of target receptor expression with positron emission tomography, and the β--emitter, lutetium-177, for targeted radiotherapy. Innovations in radioisotope technology and biomolecular therapies are likely to drive the future clinical development of radiopharmaceuticals based on radiometals. New chelator-peptide and chelator-protein bioconjugates will underpin nuclear medicine advances in molecular imaging and radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85082095333&partnerID=8YFLogxK

U2 - 10.1021/acs.bioconjchem.0c00015

DO - 10.1021/acs.bioconjchem.0c00015

M3 - Review article

C2 - 31990543

VL - 31

SP - 483

EP - 491

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 3

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454